Hepatitis B virus vaccine for patients with hepatitis C virus infection

Infection

Volumn 28, Issue 6, 2000, Pages 341-345

  Chlabicz, S ^a   Grzeszczuk, A ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

HBV vaccine; Hepatitis B virus (HBV); Hepatitis C virus (HCV); Immunogenicity

Indexed keywords

HEPATITIS B VACCINE; RECOMBINANT ALPHA2B INTERFERON; ROPHERON;

DRUG SAFETY; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NAUSEA; REVIEW; SUPERINFECTION; VOMITING;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RISK FACTORS;

EID: 0033665967     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s150100070002     Document Type: Review

References (72)

1. Hepatitis C Global prevalence
2. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
3. Current and future therapies for HCV infection: What should the end point for treatment be?
4. Consensus Panel: EASL International Consensus Conference on Hepatitis C
5. Natural history of hepatitis C: Its impact on clinical management
6. Factors associated with severity and disease progression in chronic hepatitis C
7. Occult hepatitis B infection in patients with chronic hepatitis C liver disease
8. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan
9. The role of hepatitis B virus infection and haevy smoking in hepatitis C virus-related hepatocellular carcinoma
10. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients
11. NIH consensus development conference targets prevention and management of hepatitis C
12. Prospective study of hepatitis B vaccination in patients with chronic hepatitis C
13. Epidemiology of hepatitis C
14. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients
15. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
16. Serologic markers of viral hepatitis A, B, C, and D in patients with haemophilia
17. The prevalence of hepatitis C virus infection in the United States 1988 through 1994
18. Antiobody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland
19. Prevalence of hepatitis C in a chemically dependent population
20. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency and human T-lymphotropic viruses
21. Risk factors for hepatitis C virus infection in United States blood donors
22. A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States
23. Hepatitis C in hospital employees with needlestick injuries
24. Hepatitis C virus infection in dialysis and renal transplantation
25. National surveillance of dialysis associated diseases in the United States, 1995
26. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP)
27. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,520 pregnant women
28. HCV and HBV coexist in HBsAg-negative patients with HCV viraemia: Possibility of coinfection in these patients must be considered in HBV-high endemic area
29. Prevalence of anti-HCV antibodies in patients with chronic liver disease and its relationship to HBV and HDV infections
30. Performance characteristics and results of a large-scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C: Results of the national Hepatitis Screening Survey
31. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B
32. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus
33. Viral replication in patients with concomitant hepatitis B and C virus infections
34. The significance of antibody to hepatitis C in patients with chronic hepatitis B
35. Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses
36. Clinical and virological profiles in patients with multiple hepatitis virus infections
37. Characteristics of patients with dual infection by hepatitis B and C viruses
38. Superinfection with hepatitis C virus in patients with symptomatic chronic hepatitis B
39. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma
40. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
41. Fulminant hepatic failure in acute hepatitis C: Increased risk in chronic carriers of hepatitis B virus
42. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis
43. The treatment of chronic viral hepatitis
44. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis
45. Impaired response to alpha interferon in patients with an inapparent hepatitis B and C virus coinfection
46. Hepatitis B immunization: Vaccine types, efficacy and indications for immunization
47. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations
48. Vaccines to prevent viral hepatitis
49. Improving the response to hepatitis B vaccine
50. Effect of anatomic injection site, age, and smoking on the immune response to hepatitis B vaccination
51. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers
52. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus infection
53. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination
54. Immunogenicity of hepatitis B vaccine in renal transplant recipients
55. Response to hepatitis B vaccination by liver transplant candidates
56. Response to hepatitis B vaccination in patients with severe liver disease. Absence of an HLA effect
57. Over a decade of experience with a yeast recombinant hepatitis B vaccine
58. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C
59. Recombinant hepatitis B vaccine immunogenicity in presence of hepatitis C virus seropositivity
60. Hepatitis B vaccination in patients with chronic hepatitis C
61. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
62. Hepatitis B vaccination of patients with chronic liver disease
63. Randomized comparative trial of interferon-α versus placebo in hepatitis B vaccine non-responders and hyporesponders
64. Recombinant interferon as adjuvant to hepatitis B vaccine in the haemodialysis patients
65. Antibody level after hepatitis B vaccination in haemodialysis pateints: Influence of hepatitis C virus infection
66. Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in haemodialysis patients
67. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in haemodialysis patients
68. Hepatitis B vaccine in haemodialysis patients with hepatitis C viral infection
69. Recombinant hepatitis B vaccine use in chronic haemodialysis patients. Long-term evaluation and costeffectiveness analysis
70. Response to HBV vaccine in relation to anti-HCV and anti-HBc positivity: A study in intravenous drug users
71. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: A randomized clinical trial
72. Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or preS2+S antigens